Coherus BioSciences (NASDAQ:CHRS) just reported results for the first quarter of 2024.
- Coherus BioSciences reported earnings per share of -32 cents. This was below the analyst estimate for EPS of -24 cents.
- The company reported revenue of $77.06 million.
- This was 3.97% worse than the analyst estimate for revenue of $80.25 million.